[go: up one dir, main page]

NO20080399L - Farmasoytiske sammensetninger for forlenget avgivelse, samt fremgangsmater for fremstilling derav - Google Patents

Farmasoytiske sammensetninger for forlenget avgivelse, samt fremgangsmater for fremstilling derav

Info

Publication number
NO20080399L
NO20080399L NO20080399A NO20080399A NO20080399L NO 20080399 L NO20080399 L NO 20080399L NO 20080399 A NO20080399 A NO 20080399A NO 20080399 A NO20080399 A NO 20080399A NO 20080399 L NO20080399 L NO 20080399L
Authority
NO
Norway
Prior art keywords
methods
pharmaceutical compositions
preparation
well
compositions
Prior art date
Application number
NO20080399A
Other languages
English (en)
Inventor
Rajesh Jain
Chand Kour Jindal
Sukhjeet Singh
Sanjay Boldhane
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080399(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of NO20080399L publication Critical patent/NO20080399L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives farmasøytiske sammensetninger for forlenget frigivelse omfattende idet minste ett aktivt middel, eller dets tautomere former, analoger, isomerer, polymorfer, solvater, eller salter derav; fortrinnsvis tilveiebringes et antiviralt aktivt middel. Også tilveiebrakt er en fremgangsmåte for fremstilling av slike sammensetninger, og fremgangsmåter for å anvende slike. Sammensetningene for forlenget frigivelse ifølge foreliggende oppfinnelse er i stand til å avgi det aktive middel på ønsket måte for en forlenget tidsperiode.
NO20080399A 2005-06-29 2008-01-21 Farmasoytiske sammensetninger for forlenget avgivelse, samt fremgangsmater for fremstilling derav NO20080399L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1680DE2005 2005-06-29
PCT/IN2006/000225 WO2007000779A2 (en) 2005-06-29 2006-06-29 Pharmaceutical sustained release compositions and processes thereof

Publications (1)

Publication Number Publication Date
NO20080399L true NO20080399L (no) 2008-03-31

Family

ID=37027780

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080399A NO20080399L (no) 2005-06-29 2008-01-21 Farmasoytiske sammensetninger for forlenget avgivelse, samt fremgangsmater for fremstilling derav

Country Status (15)

Country Link
US (1) US20090099154A1 (no)
EP (1) EP1912628A2 (no)
JP (1) JP2009500318A (no)
CN (1) CN101212957A (no)
AR (1) AR055070A1 (no)
AU (1) AU2006263338A1 (no)
BR (1) BRPI0613070A2 (no)
CA (1) CA2613407A1 (no)
CR (1) CR9705A (no)
EA (1) EA200800162A1 (no)
MX (1) MX2008000084A (no)
NO (1) NO20080399L (no)
RS (1) RS20070512A (no)
TN (1) TNSN07490A1 (no)
WO (1) WO2007000779A2 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
JP5295952B2 (ja) * 2006-06-08 2013-09-18 イェール ユニバーシティー 浸透圧性溶質を回収するため溶質回収システムおよび回収方法
WO2008072960A1 (en) * 2006-12-15 2008-06-19 Campina Nederland Holding B.V. Extended release excipient and its use
EP1935411A1 (en) * 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
BRPI0807807A2 (pt) * 2007-01-25 2014-06-17 Panacea Biotec Ltd " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ".
ES2574836T3 (es) 2007-06-08 2016-06-22 Boehringer Ingelheim International Gmbh Formulación de liberación prolongada de nevirapina
WO2009051022A2 (en) * 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
JP6045347B2 (ja) * 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
WO2011117875A1 (en) * 2010-03-26 2011-09-29 Hetero Research Foundation Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium
KR20120055313A (ko) * 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
CN102058553B (zh) * 2010-12-28 2012-10-10 哈药集团三精制药股份有限公司 阿昔洛韦缓释片及其制备方法
CA2847614C (en) 2011-09-30 2018-10-23 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
FR2983409B1 (fr) * 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法
KR101729096B1 (ko) 2012-03-21 2017-04-21 코스메덤 바이오사이언스, 인코퍼레이티드 통증, 가려움증 및 염증을 치료하기 위한 국소 투여된 스트론튬-함유 복합체
JP5758552B2 (ja) * 2013-05-08 2015-08-05 全星薬品工業株式会社 機能性高分子皮膜で被覆された高含量薬物粒子およびそれを含む錠剤ならびにそれらの製造方法
SI3033076T1 (sl) * 2013-08-14 2021-01-29 Evonik Operations Gmbh Sestavek za oplaščenje
WO2015048153A1 (en) * 2013-09-24 2015-04-02 Cosmederm Bioscience, Inc. Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus
CN103705933A (zh) * 2013-12-18 2014-04-09 北京科源创欣科技有限公司 奥卡西平药物组合物及制备方法
JP6532765B2 (ja) * 2014-06-06 2019-06-19 株式会社ファンケル 即効性成分と持続性成分を含む錠剤
SI3223797T1 (sl) * 2014-11-26 2020-06-30 Evonik Operations Gmbh Farmacevtski ali nutracevtski sestavek z odpornostjo na vpliv etanola
CN104666267B (zh) * 2015-03-27 2017-08-08 康普药业股份有限公司 一种阿昔洛韦药物组合物
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP7390695B2 (ja) * 2017-02-03 2023-12-04 株式会社東洋新薬 錠剤及び錠剤の製造方法
CN106943356B (zh) * 2017-05-10 2019-11-08 武汉人福药业有限责任公司 一种泛昔洛韦缓释颗粒剂及其制备方法
JP6958856B2 (ja) * 2017-08-09 2021-11-02 日本臓器製薬株式会社 錠剤
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
CN109466152B (zh) * 2018-09-04 2021-01-26 浙江罗奇泰克科技股份有限公司 一种高导热铁基板的制作方法
WO2024176162A1 (en) * 2023-02-22 2024-08-29 Sun Pharmaceutical Industries Limited Stable pharmaceutical composition of histamine h2‐receptor antagonist

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286723B6 (cs) * 1991-01-30 2000-06-14 The Wellcome Foundation Limited Tablety dispergovatelné ve vodě
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US20030134864A1 (en) * 1996-02-07 2003-07-17 Smithkline Beecham P.L.C. Activity of penciclovir against epstein-barr virus
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
ID29843A (id) * 1998-09-14 2001-10-18 Ranbaxy Lab Ltd Sistem pemberian obat melalui mulut yang dikontrol secara teratur yang memberikan pengontrolan tempat dan bersifat sementara
WO2002102415A1 (en) * 2001-06-18 2002-12-27 Blue Cross Laboratories Limited Gastric floating system
US20060159752A1 (en) * 2002-08-14 2006-07-20 Jain Girish K Extended release matrix tablets
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery

Also Published As

Publication number Publication date
AU2006263338A2 (en) 2008-06-05
CN101212957A (zh) 2008-07-02
WO2007000779A2 (en) 2007-01-04
MX2008000084A (es) 2008-03-18
JP2009500318A (ja) 2009-01-08
TNSN07490A1 (en) 2009-03-17
EP1912628A2 (en) 2008-04-23
US20090099154A1 (en) 2009-04-16
AU2006263338A1 (en) 2007-01-04
EA200800162A1 (ru) 2008-06-30
RS20070512A (sr) 2009-01-22
AR055070A1 (es) 2007-08-01
WO2007000779A3 (en) 2007-06-28
CA2613407A1 (en) 2007-01-04
BRPI0613070A2 (pt) 2010-12-21
CR9705A (es) 2008-10-30

Similar Documents

Publication Publication Date Title
NO20080399L (no) Farmasoytiske sammensetninger for forlenget avgivelse, samt fremgangsmater for fremstilling derav
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
NO20075113L (no) Proteinkinaseinhibitorer
TW200728307A (en) Novel spirochromanone derivatives
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
NO20070249L (no) Pyrrazolo-pyrimidin derivater
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20085257L (no) Purinonderivater som HM74a-agonister
NO20070339L (no) 1-aza-bicyklo[3 3.1]nonaner
TW200613243A (en) Novel compounds
NO20090664L (no) Purinderivater som A2A-agonister
SG171471A1 (en) New benzimidazole derivatives
MX2007012212A (es) 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa.
NO20090779L (no) 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister
NO20075637L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater som medikamenter for behandling av infertilitet
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
TW200800984A (en) New compounds
TW200704633A (en) Process for the preparation of sulfonamide derivatives
TW200734333A (en) Pure and stable tiotropium bromide
UA88910C2 (ru) Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application